Charles Marcus MBBS, Presenter: Nothing to Disclose

Antoniou Alexander MD, Abstract Co-Author: Nothing to Disclose

John Crandall, Abstract Co-Author: Nothing to Disclose

Richard L. Wahl MD, Abstract Co-Author: Patent holder, Naviscan, Inc Patent holder, GlaxoSmithKline plc Patent holder, Spectrum Pharmaceuticals, Inc Research Consultant, GlaxoSmithKline plc Research Consultant, Nihon Medi-Physics Co, Ltd Research support, General Electric Company Research support, Molecular Insight Pharmaceuticals, Inc Research support, Cell Point LLC

Rathan M. Subramaniam MD, PhD, Abstract Co-Author: Speakers Bureau, Eli Lilly and Company

1. Review the value of the newly FDA-approved radium-223 in the management of osseous metastases in patients with CRPC. 2. Discuss the radiobiology, radiopharmaceutical administration protocol, efficacy, outcome benefits, drug interactions, and possible adverse effects. 3. Case illustration of patients treated with radium-223.  

• Fundamentals of osseous metastasis and prevalence in prostate cancer • Current treatment options, prognostic factors and disease course in prostate cancer • The role of radium-223 in the management cascade of patients with prostate cancer • Radiobiology of radium-223 • Effect of radium-223 on the morbidity, disease progression, and survival in patients with prostate cancer • The approved administration protocol for radium-223 • The possible adverse effects to anticipate and measures to prevent them • The use of concurrent medications while administering radium-223 • Possible future potential uses of radium-223  

http://abstract.rsna.org/uploads/2014/14018103/14018103_pnop.pdf

Marcus, C, Alexander, A, Crandall, J, Wahl, R, Subramaniam, R, The Role of Radium-223 in the Management of Osseous Metastasis in Castration-resistant Prostate Cancer (CRPC).  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14018103.html